CBIO — CRESCENT BIOPHARMA INC.
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying CBIO?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their CBIO position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).
- +1 tracked investor added or increased positions last quarter (George Soros)
- +3 tracked investors reported holding CBIO at their latest filing
- −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About CRESCENT BIOPHARMA INC. (CBIO)
CRESCENT BIOPHARMA INC. (CBIO) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $7M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in CBIO
How many top investors track CBIO
A small number of top investors own this.
CBIO Ownership Composition
How CRESCENT BIOPHARMA INC. is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant95.6%
- Macro4.4%
Tracked investors currently reporting CBIO
1 tracked investor has since exited this position — listed separately below.
- Izzy EnglanderSep 30, 2026Millennium ManagementShares84.9KValue$1.2M% Portfolio0.00%
- Ken GriffinSep 30, 2026Citadel AdvisorsShares349.7KValue$5.1M% Portfolio0.00%
- George SorosSep 30, 2026Soros Fund ManagementShares20KValue$291.8K% Portfolio0.00%
Previously held CBIO
These investors reported CBIO in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 300K | $5.4M | Jun 30, 2026 |
Recent activity
- Sold$0(-100.00%)Nov 16, 2026
- New$291.8KNov 13, 2026
- New$3.6MFeb 17, 2026
- Unchanged$5.5M(0.00%)May 15, 2026
- Unchanged$5.4M(0.00%)Aug 14, 2026
Frequently asked questions
- How many institutional investors hold CBIO?
- 3 tracked institutional investors disclosed a position in CBIO (CRESCENT BIOPHARMA INC.) in their most recent 13F filing.
- Who is the largest institutional holder of CBIO?
- Izzy Englander, Millennium Management, holds the largest disclosed position in CBIO, valued at $7M.
- Did institutional ownership of CBIO increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 fully exited CBIO.
- Where does this CBIO ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.